21:48 on September 2, 2021, Beijing time, OTC market in the United StatesWUHAN GENERAL GP (WUHN.us)The stock changed, and the stock price soared by 5.62%. As of press time, the stock was trading at US $0.729 per share, with a turnover of 9800 shares.Turnover rate0.03%, amplitude 0.07%.
Recent financial data show that the stock has an operating income of $2362.00.Net profit-$281603.00, earnings per share-$0.010Gross profit419.00 US dollars, with a price-to-earnings ratio of-87.20 times.
In terms of agency rating, there is currently no agency to make "buy, hold, sell" recommendations on the stock.
In the pharmaceutical industry where WUHAN GENERAL GP's shares are located in the US OTC market, the overall increase is 0.27%. Among its related stocksREGENCELL BIOSCIENCE HLDGS LTD、Syneos Health Inc Com Usd0.01 Cl A、Painreform LtdSyneos Health Inc Com Usd0.01 Cl A, Painreform Ltd,Adamis Pharmaceuticals CorporationIt is more active, with turnover rates of 2.31%, 1.08% and 1.03% respectively. The related stocks with larger amplitudes are Syneos Health Inc Com Usd0.01 Cl A, REGENCELL BIOSCIENCE HLDGS LTD and Painreform Ltd, with amplitudes of 10.96%, 9.86% and 6.64%, respectively.
About WUHAN GENERAL GP in American OTC Market: M2Bio Sciences Inc, formerly known as WUHAN GENERAL GP Group (China) Co., Ltd., is an alternative pharmaceutical company dedicated to the application of emerging technologies and clinical research and health applications of cannabinol (CBD)-based drugs in the human and pet care industries in Canada, the United States, Europe and Australia for cancer, cardiovascular disease, and mental illness. Chronic pain and other diseases. It provides medical-grade CBD products and quality patient care.
(the above content is completed by Money Call, a self-selected intelligent machine writer, and is only used as a reference for users to look at the market, not as a basis for transaction. )